Arcturus Therapeutics' (ARCT) "Overweight" Rating Reiterated at Cantor Fitzgerald

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report)'s stock had its "overweight" rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued on Friday,Benzinga reports.

Several other analysts have also issued reports on ARCT. HC Wainwright restated a "buy" rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Friday, February 14th. Wells Fargo & Company lowered their price objective on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday. Finally, BTIG Research initiated coverage on Arcturus Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $41.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Arcturus Therapeutics has an average rating of "Buy" and an average target price of $59.20.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT traded down $1.08 during trading on Friday, hitting $13.21. The stock had a trading volume of 568,323 shares, compared to its average volume of 425,942. Arcturus Therapeutics has a 12 month low of $12.75 and a 12 month high of $45.00. The company's 50-day moving average price is $16.91 and its two-hundred day moving average price is $18.50. The company has a market capitalization of $357.82 million, a PE ratio of -5.95 and a beta of 2.96.

Remove Ads

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million. As a group, equities analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company's stock valued at $52,819,000 after acquiring an additional 712,650 shares in the last quarter. ARK Investment Management LLC increased its position in shares of Arcturus Therapeutics by 6.9% during the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company's stock valued at $48,765,000 after purchasing an additional 136,074 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Arcturus Therapeutics by 6.8% during the fourth quarter. Vanguard Group Inc. now owns 1,684,561 shares of the biotechnology company's stock worth $28,587,000 after acquiring an additional 107,635 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in Arcturus Therapeutics by 129.7% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company's stock worth $14,409,000 after purchasing an additional 479,482 shares during the last quarter. Finally, Woodline Partners LP grew its stake in shares of Arcturus Therapeutics by 3.5% during the fourth quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company's stock valued at $13,693,000 after buying an additional 26,956 shares during the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.